KetoSwiss AG Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Basel Switzerland

Primary Industry

Pharmaceuticals

About

Based in Switzerland, and founded in 2017 by its CEO Dr. Elena Gross, KetoSwiss AG operates as a biotechnology company that develops therapeutic products mitigating neurological diseases such as migraines and brain aging. In August 2023, KetoSwiss AG raised approximately EUR 4.37 million in pre-series A funding led by William K. Warren Foundation, with participation from Healthspan Capital and R42. KetoSwiss AG developed MigraKet, a product for the dietary management of migraine that contains micronutrients necessary for energy production in addition to macronutrients that are efficacious and close to the root cause of migraine. The MigraKet active substance is an endogenous metabolite – a Ketone body, that can be used by the human brain as an alternative source of fuel to glucose, when glucose utilization or transport is compromised.

Current Investors

William K. Warren Foundation, BaselArea.swiss, R42

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Mental Health Services, Therapeutic Devices, Pharmaceuticals

Website

www.keto.swiss

Verticals

Manufacturing

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.